Pockets of weakness in the market have captured Cramer's attention. Is the selling really warranted?
Novartis was sued on Tuesday by the United States, which accused the Swiss drug maker of using kickbacks to induce pharmacies to steer thousands of patients to its drug.
Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.
Big pharma is abandoning antibiotic research at a time when fears over superbugs are growing at an alarming rate, leaving smaller firms to fill the breach.
It will take a mix of approaches to make health care more affordable, Johnson & Johnson CEO Alex Gorsky told CNBC.
Antibiotic-resistant bacteria—often called "superbugs"—are entering the nation's food system and endangering consumers at an alarming rate, according to an analysis of government data.
A British professor says that drug abuse helped bring about the financial crisis, but he may have pinned the blame on the wrong drug.
Stocks bounced back on Tuesday. But what should you make of the leadership?
Some cancers could be cured within the next couple of years, Celgene CEO Robert Hugin told CNBC.
Eli Lilly plans to slash 1,000 sales jobs in a "major restructuring," a source familiar with the plans said.
China is handling an outbreak of bird flu much better than in the past, Sanofi CEO Chris Viehbacher told CNBC on Thursday.
Markets can expect a wave of new medicines over the next few years, said John Lechleiter, Eli Lilly's president and CEO.
Jim Cramer says that although some big investors have warned of a growing bubble, several areas of the market suggest that the rally is for real.
John Lechleiter, Eli Lilly's chairman, president and CEO, discusses the company's drug pipeline as its stock nears a 52-week high.
Daniel O'Day, head of pharmaceutical operations at Roche, tells CNBC that the company haven't seen a huge effect from the Sequester in the US.
Andrew Weiss, head of Pharma at Vontobel, tells CNBC that Roche delivered earnings in line with expectations.
While the other big pharma stocks roared, Cramer said one was left behind.
True many pay dividends, but don’t paint all pharma companies with the same brush.
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
In addition to superbugs' deadly human toll, associated health costs run into the billions. Some warn that we may never win our war against them as research tapers off.